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Abstract
Background: Pancreatic acinar cell carcinoma (ACC) is a rare tumor entity with an unfavorable prognosis. Recent
whole-exome sequencing identified p53 mutations in a subset of human ACC. Activation of the mammalian target of
rapamycin (mTOR) pathway is associated with various pancreatic neoplasms. We thus aimed at analyzing whether
activation of mTOR with a concomitant loss of p53 may initiate ACC.
Methods: We generated transgenic mouse models in which mTOR was hyperactivated through pancreas-specific,
homozygous tuberous sclerosis 1 (Tsc1) deficiency, with or without deletion of p53 (Tsc1-/- and Tsc1-/-; p53-/-). Activity of
mTOR signaling was investigated using mouse tissues and isolated murine cell lines. Human ACC specimens were used
to corroborate the findings from the transgenic mouse models.
Results: Hyperactive mTOR signaling in Tsc1-/- mice was not oncogenic but rather induced a near-complete
loss of the pancreatic acinar compartment. Acinar cells were lost as a result of apoptosis which was
associated with p53 activation. Concomitantly, ductal cells were enriched. Ablation of p53 in Tsc1-deficient
mice prevented acinar cell death but promoted formation of acinar cells with severe nuclear abnormalities.
One out of seven Tsc1-/-; p53-/- animals developed pancreatic tumors showing a distinctive tumor morphology,
reminiscent of human ACC. Hyperactive mTOR signaling was also detected in a subset of human ACC.
Conclusion: Hyperactive mTOR signaling combined with loss of p53 in mice induces tumors similar to human ACC.
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Background
Pancreatic acinar cell carcinoma (ACC) is a rare exo-
crine cancer which accounts for 1–2 % of pancreatic ma-
lignancies [1, 2]. On histological and molecular levels,
ACCs display certain features of normal pancreatic acini
by expressing exocrine enzymes (e.g., trypsin) and by
forming small glandular structures [3]. In comparison to
pancreatic ductal adenocarcinoma (PDAC), ACCs tend
to have a relatively favorable tumor biology which is
more likely to respond to the available therapies [4–7].
Historically, it is conceived that ACCs do not share
typical mutations of PDAC such as p53 [3, 8]. How-
ever, this view has recently been updated by whole-
exome sequencing of ACCs [9]. Here, 13 % of ACC
samples contained somatic p53 mutations and 39 %
of them had a loss of heterozygosity at the p53 locus
[9]. Therefore, it is likely that the p53 pathway ac-
tively participates in the development of a subset of
ACCs.
The mammalian target of rapamycin (mTOR) is an
atypical serine/threonine kinase that interacts with other
proteins to form two functional complexes: mTORC1
and mTORC2 [10]. Particularly, mTORC1 (referred to
hereinafter as mTOR) integrates a variety of intracellular
and extracellular cues and is a key regulator of protein
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synthesis. It potentially influences carcinogenesis at
various stages including cancer initiation and metasta-
sis [11, 12]. The tuberous sclerosis 1 and 2 complex
(Tsc1-Tsc2 complex) negatively regulates mTOR activ-
ity [13–16].
There is increasing evidence that mTOR activation is
a common event in the development of various pancre-
atic tumors such as PDAC, a subset of cystic tumors and
pancreatic neuroendocrine tumors (PNETs, [17–19]).
Furthermore, we have previously demonstrated that the
oncogenic effect of mTOR largely relies on its activation
pattern: PI3K/Akt (phosphatidylinositol-4, 5-
bisphosphate 3-kinase/protein kinase B)-mediated
mTOR signaling induced cystic pancreatic lesions
whereas oncogenic Mek/Erk-induced mTOR signaling
promoted metastatic PDACs [18]. Since p53 interacts
with mTOR signaling at multiple levels via the Tsc1-
Tsc2 complex [20, 21], we aimed to analyze whether
hyperactivated mTOR signaling with a loss of p53 may
specify ACC.
Results
Tsc1 deficiency triggers loss of acinar cells in the exocrine
pancreas
Previously, we generated pancreas-specific Tsc1-haploin-
sufficient (p48Cre/+; Tsc1fl/+) mice by crossing the
Ptf1aCre/+ line (also known as p48Cre/+) with the Tsc1fl/fl
line in which one allele of Tsc1 is specifically ablated in
pancreatic progenitors during embryonic development
and continuously deleted in pancreatic acinar cells in
adulthood. However, neither overt pathologies nor
hyperactive mTOR signaling was observed in the pan-
creata of these animals [18]. To further investigate the
role of mTOR signaling in pancreatic exocrine physi-
ology, we thus generated transgenic p48Cre/+; Tsc1fl/fl
mice (herein referred to as Tsc1-/-). A complete loss of
Tsc1 expression in the pancreata of these transgenic ani-
mals was previously confirmed [18]. The p48Cre/+; Tsc1fl/
+ mice (herein referred to as Tsc1+/-) were used as
controls.
All Tsc1-/- mice died between the age of 100 days
and 224 days (n = 5; median survival: 133 days;
Fig. 1a). Histological examination of Tsc1-/- pancreata
revealed a destruction of the normal pancreatic acinar
cell compartment (50–80 %) with a relative enrich-
ment of ductal cells. However, no such changes were
observed in Tsc1-/+ (n = 14) pancreata (Fig. 1b). The
number of acinar cells was reduced and the residual
acinar cells were surrounded by ductal cells in Tsc1-/-
pancreata (α-amylase and Krt19 double-IF; Fig. 1c).
Similar to previous observations in Tsc2-deficient
mice [22], hyperglycemic episodes were observed in
two Tsc1-/- mice by the time of death/sacrifice and
the number of β cells was also significantly reduced
(blood glucose levels of 370 and 590 mg/dl, respect-
ively; normal: 160 to 200 mg/dl, insulin and glucagon
double-IF; Fig. 1d). These data suggest that the Tsc1-/-
mice suffered from both exocrine and endocrine
insuffiency by the time of sacrifice. However, the
Tsc1-/+ pancreata were histologically normal. Taken
together, Tsc1 deficiency caused loss of functional par-
enchymal cells in both the exocrine and endocrine
compartment of the pancreas. However, Tsc1 haploin-
sufficiency did not result in a gross pathological
phenotype.
Next, we aimed to determine whether Tsc1 deficiency
resulted in hyperactive mTOR signaling in the pancreas.
IHC studies revealed that residual acinar cells in Tsc1-/-
animals were strongly positive for p-mTORSer2448 and p-
S6Ser235/236 while the acinar cells in Tsc1-/+ mice were
only weakly positive (Fig. 1e, f ). As a feedback response
to hyperactive mTOR signaling, Pten was induced in re-
sidual acinar cells (Fig. 1g). No such differences were ob-
served in Tsc1-/+ pancreata.
Hyper-activated mTOR signaling induces p53 and
apoptosis of acinar cells
We then set out to investigate potential reasons for the
loss of acinar cells induced by hyper-activated mTOR
signaling. Previous studies in mouse embryonic fibro-
blasts (MEFs) showed that hyper-activated mTOR ren-
dered these cells susceptible to p53-dependent apoptosis
[23]. Thus, expression of cleaved-caspase 3 (a marker of
apoptosis) and p53 was analyzed, revealing that the re-
sidual acinar cells in Tsc1-/ - pancreata were apoptotic
and were strongly positive for nuclear p53 (Fig. 2a, b). In
addition, an increased proliferation rate was observed in
these residual acinar cells (Fig. 2c, d). Such changes were
not seen in Tsc1-/+ pancreata; Fig. 2a, b and c).
Loss of p53 and Tsc1 promote acinar cell transformation
To confirm that acinar cell apoptosis was p53-
dependent, we inactivated p53 in the context of Tsc1 de-
ficiency. Thus, p48Cre/+; p53fl/fl; Tsc1fl/fl (referred to here-
inafter as: p53-/-; Tsc1-/-) mice were generated.
Surprisingly, additional ablation of p53 did not prolong
the survival of Tsc1-/- mice: all p53-/-; Tsc1-/- mice died
between the age of 84 days and 237 days (n = 7; median
survival: 101 days vs. 133 days in Tsc1-/- mice, n = 5;
Fig. 3a); however, neither significant loss of acinar cells
nor death of acinar cells was observed. Instead, histo-
logical examination of p53-/-; Tsc1-/- pancreata revealed
occurrence of dysplastic acinar cells in all animals
(Fig. 3b, upper panel). These cells were characterized by
an increased nuclear-cytoplasmic ratio with moderate to
severe nuclear atypia with coarse granular chromatin,
multiple nucleoli and single atypical mitoses. Addition-
ally, nodular hyperplasia in acinar cells (circumscribed
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aggregates of acinar cells with distinct tinctorial differ-
ences to the surrounding acinar cells) were observed in
4 mice (Fig. 3b, lower panel); further, a large pancreatic
tumor (Fig. 3c, Additional file 1: Figure S1A) was seen in
one out of seven mice. Histological examination of the
tumor revealed that the tumor cells were highly
proliferative and showed distinctive tumor morphology
reminiscent of human ACC (Fig. 3c) with an acinar to
solid growth pattern and neoplastic cells with an ampho-
philic to eosinophilic granular cytoplasm. Positivity of
the tumor cells for secretory enzymes such as Trypsin 3
(protease, serine 3) and α-Amylase (Additional file 1:
a b c d
Fig. 2 Hyperactivated mTOR signaling induces p53 and apoptosis in acinar cells. (a-c) Representative IHC pictures show in vivo activation of p53,
apoptosis (cleaved-caspase 3), increased proliferation (p-Histone H3 (p-HH3)) in pancreatic tissues from Tsc1-/- mice, scale bar: 50 μm; (d) Quantification





Fig. 1 Tsc1 deficiency triggers loss of acinar cells in the exocrine pancreas. (a) Kaplan–Meier survival analysis shows Tsc1-/- mice survival time
(median survival: 131 days; n = 5); (b), Representative H&E-stained sections of Tsc1-/+ and Tsc1-/- pancreata show significant loss parenchymal cells
in Tsc1-/ -mice, but not in Tsc1-/+ mice; scale bar: 50 μm (c-d), Co-IF for Krt19, α-amylase, glucagon and insulin show the loss of tissue homeostasis
in the endocrine and exocrine compartment of Tsc1-/- pancreata; scale bars: 50 μm; (e-g), Representative IHC pictures show distinct in vivo
activation of mTOR signaling (p-mTORSer2448 and p-S6Ser235/236) and induction of Pten in pancreatic tissues from Tsc1-/- mice, scale bar: 50 μm










Fig. 3 (See legend on next page.)
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Figure S1B) underscored the acinar origin of the
neoplasia.
In regard to the endocrine compartment, however, we
observed a phenotype as described for Tsc1-/- pancreata:
no islets were seen in any of the p53-/-; Tsc1-/- pancreata,
except for one with a large ACC-like tumor. Since no
difference in survival of p53-/-; Tsc1-/- and Tsc1-/- mice
was found, uncontrolled diabetes mellitus seems to be
the cause of death in these animals. Such changes were
not seen in p53-/-; Tsc1-/+ pancreata (Additional file 1:
Figure S1C).
To investigate signal changes occurring in p53-/-;
Tsc1-/+ and p53-/-; Tsc1-/- pancreata, we performed a set
of phosphorylation stainings for Erk, Akt, mTOR and
S6. This analysis revealed that pancreatic epithelial cells
in p53-/-; Tsc1-/+ mice and tumor cells (and atypical aci-
nar cells) in p53-/-; Tsc1-/- mice were generally devoid of
p-AktSer473 and p-Erk1/2Thr202/Tyr204 (Fig. 3d, e); pancre-
atic acinar cells of p53-/-; Tsc1-/+ mice had detectable
levels of p-mTORSer2448 and p-S6Ser235/236; however, the
staining intensities in the tumor cells (and atypical aci-
nar cells) of p53-/-; Tsc1-/- mice were more pronounced
(Fig. 3f, g). These data suggest that hyper-activated
mTOR signaling in p53-/-; Tsc1-/- pancreata was not
dependent on either the Mek/Erk nor the PI3K/Akt
cascade.
In a next step, we established a set of mouse cell lines
from p53-/-; Tsc1-/+ (911 and 961 cells) and p53-/-; Tsc1-/-
mice (946 F and 946 cells from ACC-like tumors). As
previously reported, a set of p53-deficient cell lines
underwent epithelial-to-mesenchymal transition (EMT)
and exhibited fibroblast-like morphologies in vitro
(Fig. 3h, upper panel) [24], except for one clone (946),
which showed a stable epithelial morphology (Fig. 3h,
lower panel). Cell lines that had undergone EMT (911,
961 and 946 F) expressed low levels of E-Cadherin but
high levels of vimentin, compared to those without
EMT features (946 cells, Fig. 3i). Neither was Tsc1 de-
tected in the Tsc1-deficient cell lines (946 and 946 F)
nor was p53 found in p53-deficient cells (911, 961, 946
and 946 F cells, Fig. 3i, and IHC of p53: Additional file
1: Figure S2A). To test clonogenicity and tumorigenicity
of these cell lines, we performed orthotopic implantation
into wild-type (WT) mice and subcutaneous injection
into BALB/c nude mice. None of the tested cells lines
were able to form tumors in WT mice (n = 24). How-
ever, tumors formed at 67 % of the sites (16/24) injected
with cells with EMT features (cell lines 911, 961 and
946 F), while no tumors were found at the sites (0/3)
injected with the cells without EMT features (946;
BALB/c nude mice). An overview of the transplanted
cells, mouse numbers and tumor formation is provided
in Additional file 2: Table S1. No difference in prolifera-
tion of these cell lines in vivo was detected by quantify-
ing the number of phospho-Histone H3 (pHH3) positive
cells (Additional file 1: Figure S2B).
To further confirm the signal changes in vitro, we cul-
tured p53-/-; Tsc1-/+ and p53-/-; Tsc-/- cell lines under
serum deprivation conditions. Only weak constitutively
active Akt or Erk signaling (as demonstrated by p-
AktSer473 and p-Erk1/2Thr202/Tyr204 staining) was ob-
served in these cell lines, but serum treatment (20 %
FBS) induced pronounced Akt and Erk activation in
these cells; though to a lesser extent in the p53-/-; Tsc1-/-
cell lines. The p53-/-; Tsc1-/+ cell lines had relatively low
levels of basal mTOR signaling (as demonstrated by p-
mTORSer2448) which was slightly increased by serum
treatment. In contrast, mTOR signaling in the p53-/-;
Tsc1-/- cells was constantly active and serum treatment
had marginal additional effects (Fig. 3j).
mTOR signaling is activated while p53 signaling is
inactivated in human ACCs
To investigate mTOR and p53 signaling in human
ACCs, 14 ACC samples were stained (Fig. 4a) with p-
mTORSer2448, p-S6Ser235/236 and p53 antibodies. This
analysis revealed that 43 % (6/14) and 64 % (9/14) of the
samples were positive for p-mTORSer2448 and p-S6Ser235/
236, respectively (Fig. 4b, c). Notably, no nuclear p53
staining was detected in any of tested samples, indicating
a universal inactivation of p53 signalling in human ACC.
(See figure on previous page.)
Fig. 3 Loss of p53 and Tsc1 promote acinar cell transformation. (a) Kaplan–Meier survival analysis shows p53-/-; Tsc1-/- mice survival time (median
survival: 101 days; n = 7) which is not different from that of Tsc1-/- mice (median survival: 133 days; n = 5); (b) Representative H&E-stained sections
of p53-/-; Tsc1-/+ and p53-/-; Tsc1-/- pancreata show pancreatic acinar cells with nuclear abnormalities (upper panel) and nodular hyperplasia (lower
panel); scale bar: 50 μm (upper panel) and 200 μm (lower panel); (c) Representative H&E-stained sections and IHC pictures show the histology of
one ACC-like tumor with a high proliferative index (p-HH3); (d-g) Representative IHC pictures show distinct in vivo activation of mTOR signaling
(p-mTORSer2448 and p-S6Ser235/236), but inactivation of Erk (p-Erk1/2Thr202/Tyr204) and Akt (p-AktSer473) in tumor cells (and atypical acinar cells) of
pancreatic tissues from p53-/-; Tsc1-/- mice, scale bar: 50 μm; (h) Phase contrast images of isolated cell lines from p53-/-; Tsc1-/+ (911 and 961) and
p53-/-; Tsc1-/- (946 and 946 F) mice show fibroblast-like (961, 911 and 946 F) and epithelial (946) morphologies, scale bar: 50 μm; (i) Western-blot
analysis demonstrates expression of Tsc1, E-Cadherin, Vimentin and p53 in p53-/-; Tsc1-/+ and p53-/-; Tsc1-/- cells; previously described cystic cells
lines isolated from P48Cre/+; Pten-/-; Tsc1-/+ mice were used as used as external controls [18]; (j) Western-blot analysis demonstrates phosphorylation
levels of p-AktSer473, p-Erk1/2Thr202/Tyr204 and p-mTORSer2448 in p53-/-; Tsc1-/+ and p53-/-; Tsc1-/- cells after fetal bovine serum (FBS) treatment for 2 h;
one of the three independent experiments is shown
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As a control, PDAC sections were stained with p53 anti-
bodies (Fig. 4d).
Discussion
The Tsc/mTOR/p53 signaling loop is a delicate feedback
system by which cells are able to cope with genotoxic
and nutritional stress [25]. mTOR activates p53 by either
increasing its protein synthesis or its stability, which in-
creases the GAP activity of the Tsc1-Tsc2 complex via
AMPK and sestrin 1/2 [20, 21]. Hence, the Tsc1-Tsc2
complex constitutes an essential component of the sig-
naling loop. It has been reported that hyperactive mTOR
signaling - caused by loss of Tsc1 or Tsc2 - induced ac-
cumulation of p53 and apoptosis in mouse embryonic fi-
broblasts upon glucose starvation [23]. Consistently, we
demonstrate that pancreatic acinar cells do not tolerate
hyperactive mTOR signaling induced by Tsc1 deficiency
and undergo apoptosis, likely in a p53-dependent way.
Additional ablation of p53 eliminated cell death, but
simultaneously promoted formation of dysplastic acinar
cells and induced a malignancy resembling ACC. How-
ever, degeneration of the endocrine compartment was
not affected by the p53 status. These data suggest that
mTOR hyperactivation-induced apoptosis of endocrine
cells is not a p53-dependent process. This argument is
in line with published data showing that impairment of
autophagy and induction of endoplasmic reticulum (ER)
stress are potentially responsible for cell death [26]. The
exact mechanisms underlying such effects remain yet to
be defined.
By analysing pancreas tissues of p53-/-; Tsc1-/- mice, we
observed that all samples displayed dysplastic acinar
cells and four out of them showed nodular hyperplasia
in the exocrine pancreas. These data suggest that the
presumed precancerous lesions indeed developed in
those mice without established ACC-like tumors. How-
ever, due to the general loss of islets in these mice, un-
controlled diabetes mellitus seems to have caused the
early death of these animals. Thus, this “compound”
phenotype in the endocrine compartment does not allow
for a sufficient follow-up of ACC-like tumor develop-
ment in our mouse models. Following this reasoning,
the only mouse developing an ACC-like tumor had the
longest survival (237 days). To resolve this issue, it is
worthwhile to specifically ablate p53 and Tsc1 in pancre-
atic acinar cells in the adult organ using an inducible
system.
Recently, Ding and co-workers reported that Tsc1 ab-
lation mediated by Neurogenin 3-Cre (Neurog3Cre;
Tsc1-/- mice) also induced “adenocarcinoma-like” lesions
showing features of ACCs [27]. Interestingly, no massive
acinar cell apoptosis/involution was described in the
pancreas of Neurog3Cre; Tsc1-/- mice. Furthermore, ACC-
like tumors developed at a relatively long latency. Of
note, the Neurog3Cre line is not a “usual” Cre line for
studying pancreatic exocrine malignancies because it
mainly mediates genetic recombination in the endocrine
compartment. Lineage tracing experiments revealed that
only a small percentage of acinar cells (around 0.8 %) in
the adult organ were Cre-positive in the Neurog3Cre line
[28]. Thus, the majority of acinar cells in Neurog3Cre;
Tsc1-/- mice are spared from genetic recombination at
the Tsc1 locus. This explains why no massive acinar cell
apoptosis was observed in Neurog3Cre; Tsc1-/- mice. This
a b
c d
Fig. 4 mTOR signaling is activated while p53 signaling is inactivated in human ACCs. (a) Representative H&E-stained sections of the histology of
human ACCs; (b-c) Representative IHC pictures show distinct in vivo activation of mTOR signaling (p-mTORSer2448 and p-S6Ser235/236) in a subset of
human ACC, but universal inactivation of p53 signalling (nuclear staining for p53), scale bar in (b) (right panel) and (c): 50 μm; scale bar in (b) (left
panel): 200 μm; (d) Representative IHC pictures show inactivation of p53 signalling (nuclear staining for p53) in ACCs, but not in PDACs; scale
bar: 50 μm
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lack of organ involution in the acinar cell compartment
allows for long-term monitoring of tumor development
in these mice. Indeed, all Neurog3Cre; Tsc1-/- mice devel-
oped ACC-like tumors by the age of 10 months. Given
the continuous DNA damage in Tsc1-deficient cells, it
remains unknown how many of the ACC-like tumors
have acquired a genetic alteration of p53 during tumor
evolution. Due to the “premature” demise of the p53-/-;
Tsc1-/- mice, the real penetrance of the mTOR-p53 axis
in initiating ACC-like tumors remains unclear. Never-
theless, two studies now provide consistent evidence that
hyperactive mTOR is the driving force for the develop-
ment of - at least a subset - of ACCs.
Conclusions
The mTOR-p53 axis constitutes an important regulatory
machinery which controls tissue homeostasis of the pan-
creas. Dysregulation of this axis contributes to the devel-
opment of ACCs. Preclinical studies testing the
effectiveness of anti-mTOR therapies in ACC mouse
models are warranted.
Methods
Patient material and tissue collection
ACC tissues were from patients who had undergone
pancreatic resections. All sample diagnoses were
confirmed histologically. Samples were fixed in parafor-
maldehyde solution for 24 h and subsequently paraffin-
embedded for histological analysis. The use of tissue for
analysis was approved by the local Ethics Committee
(Technical University Munich, #1926/07) and written in-
formed consent was obtained from the patients prior to
surgery (Department of Surgery, Klinikum rechts der
Isar).
Mouse lines
Mice containing a floxed allele of Tsc1 (005680) and of
p53 (008462) were obtained from The Jackson Labora-
tory (Bar Harbor, USA). The pancreas-specific Cre re-
combinase line Ptf1aCre/+ (also known as p48Cre/+) was a
kind gift from Roland M. Schmid and Jens T. Siveke
(Dept. of Gastroenterology, TU Munich). The wild type
(WT; C57BL/6 J) and thhe BALB/c nude mice were ob-
tained from Charles River Laboratory (Sulzfeld,
Germany).
Mouse breeding
Mouse breeding was performed and husbandry was
maintained at the specific pathogen free (SPF) mouse fa-
cility at the Technical University of Munich. The com-
pound transgenic mice were maintained on a mixed
background. All mouse experiments and procedures
were approved by the Institutional Animal Care and Use
Committees of the Technical University of Munich. All
procedures were in accordance with the Office of La-
boratory Animal Welfare and the German Federal Ani-
mal Protection Laws. All mouse experiments and
procedures were approved by Bavarian Government
(No. 55.2-1-54-2532-42-13; 55.2-1-54-2531-33-08). Un-
less otherwise stated, all animals were followed up for
up to 1.5 years or sacrificed for histological analysis if
they showed any sign of disease.
Primary cell isolation
Freshly dissected sterile tumor tissues were washed twice
with ice-cold PBS, cut into small cubes (approximately
1 mm) and dispensed into 5 ml of complete medium
containing collagenase (1.2 mg/ml). The resulting solu-
tion (mixed with tissue blocks) was incubated at 37 °C
for 0.5 h. After centrifugation at 300 rpm for 5 min, the
small tissue blocks were washed twice with collagenase-
free medium, followed by incubation at 37 °C with
medium containing collagenase for an additional 0.5 h.
After passing the undigested tissue blocks through a
100 μm nylon mesh, cell suspensions were obtained.
These cell suspensions were washed two times with
complete medium and seeded into a 10 cm2 dish.
Cell transplantation experiments
For mouse cell transplantation experiments into BALB/c
nude mice, 106 tumor cells were resuspended in 50 μl of
PBS and were injected into the left lower and right
upper flank. Tumor growth was monitored macroscopic-
ally every week. Orthotopic transplantations of mouse
cells were carried out as described previously [29, 30].
Briefly, mice were anesthetized, and a left-lateral incision
of the abdomen was made to visualize the tail region of
the pancreas. 106 tumor cells were suspended in 50 μl of
PBS and were carefully injected into the pancreatic tail.
The abdominal wall and skin were closed using running
sutures. All mice were sacrificed for histological evalu-
ation after 4 weeks.
Further materials and methods
A detailed materials and methods section is provided as
a Additional file 3.
Statistical analysis
GraphPad Prism 5 Software (GraphPad, San Diego, CA,
USA) was used for the statistical (survival) analysis. Stat-
istical significance was set at p < 0.05.
Additional files
Additional file 1: Figure S1. A, Gross pathology of one ACC-like tumor
in p53-/-; Tsc1-/- mice; B, IHC demonstrates expression of α-Amylase and
Trypsin 3 in tumors cells and acinar cells of p53-/-; Tsc1-/- and p53-/-; Tsc1-/+
mice, respectively; scale bar: 50 μm; C, Representative H&E stained section
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shows normal histology of p53-/-; Tsc1-/+ pancreata; scale bar: 50 μm.
Figure S2. A, Representative IHC pictures demonstrate the knockout
status of p53 in p53-/-; Tsc1-/- and p53-/-; Tsc1-/+ pancreata, respectively;
scale bar: 100 μm; B, Quantification of proliferating cells (marked by p-
HH3 staining) in tumors that developed after implantation of p53-/-; Tsc1-/-
(946 F) and p53-/-; Tsc1-/+ (911 and 961) cell lines into BALB/c nude mice
shows no differences; n.s.: no significant change tested by one-way
ANOVA. (PPT 38925 kb)
Additional file 2: Table S1. Tumor formation by p53-/-; Tsc1-/- or p53-/-;
Tsc1-/+ cells in wild-type (WT) and BALB/c nude mice. (DOC 28 kb)
Additional file 3: Supplementary Materials and Methods. (DOC 59 kb)
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